Mati Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Mati Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Mati Therapeutics: 12 sponsored US clinical trials, none currently recruiting.
Mati Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ocular Hypertension (OH), with 1 trials.
Top-decile sponsor footprint
Mati Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
12 total, page 1 of 1
Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure
NCT04962009
An Open-Label, Multi-Center, Clinical Study Evaluating the Effect of the NDE L68 StableFit® Punctal Plug on the Tear Lake
NCT04280653
Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract
NCT03496467
A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma
NCT02014142
A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
NCT01481051
A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
NCT01481077
A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG
NCT01037036
A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG
NCT00967811
A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma
NCT00820300
A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)
NCT00821002
Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma
NCT00845299
Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT00650702
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 10 |
Therapeutic Areas
How the Mati Therapeutics early-phase archive is shaped
12 indexed studies, none listed as recruiting (0% open); 12 completed (100%).
Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Ocular Hypertension (OH) (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Mati Therapeutics: archived-pipeline peers nationwide
Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Mati Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 archived trials
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Mati Therapeutics page
12 registered trials is a research-attention snapshot, not an endorsement of Mati Therapeutics or any single study.
- None of Mati Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Ocular Hypertension (OH) is the condition Mati Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ocular Hypertension (OH) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mati Therapeutics pipeline card: 12 registered trials from official public datasets.Report a data error.